Little Norwegian biotech will sell itself for parts, as it plans to explore 'strategic options'
A few weeks after announcing a reorganization and shutting down its only clinical trial, Nordic Nanovector has decided to essentially call it quits.
The Norwegian company revealed late Thursday afternoon that it will “explore strategic options,” biotech codespeak for selling itself and/or its assets. The move will wrap up what’s been a 13-year journey since Nordic Nanovector’s 2009 founding.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.